Search Videos and More
News
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)
Can we lower the chance of gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm? Will administering paclitaxel chemotherapy directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm help patients live longer?
News
Prehabilitation in High-Risk Oncologic Surgery: A Prospective Cohort Study (PRS III)
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
News
Adaptive Radiation Boost for Rectal Cancer (ARBOR)
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
News
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
News
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial
This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control and cure rate. The outcome for this study will be assessed over the first 2-3 years following completion of the therapy to which the patient is randomized.
News
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
News
Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced).
News
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This is a multicenter randomized control trial evaluating novel BTK degrader (BGB-16673) versus standard of care pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had progressive disease on a prior line containing a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patient are allowed but not required to have previously received venetoclax (or other BCL2 directed therapy).
News
Surgery With or Without Neoadjuvant Chemotherapy in High-Risk RetroPeritoneal Sarcoma (STRASS2)
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
News
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)
This trial is a multi-site, single-arm, phase II trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.
News
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).
News
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
The premise of DE-CART is to use adaptive radiation to improve the efficacy of traditional prostate stereotactic body radiation therapy (SBRT). The adaptive SBRT approach will deliver prostate SBRT to the entire gland and focus an even higher dose of radiation to the area(s) of tumor within the prostate.